Analyst Price Target is $52.00
▲ +65.24% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $52.00, with a high forecast of $82.00 and a low forecast of $38.00. The average price target represents a 65.24% upside from the last price of $31.47.
Current Consensus is
Buy
The current consensus among 8 investment analysts is to buy stock in Denali Therapeutics. This Buy consensus rating has held steady for over two years.
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Read More